LakeShore Co Stock Price, News & Analysis

LakeShore Biopharma Co., Ltd (LSBWF) is a global biopharmaceutical company whose securities trade on the OTC Pink Open Market under the symbol LSBWF. According to company disclosures, LakeShore Biopharma is dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The company’s warrants are quoted as LSBWF, while its ordinary shares trade under a related OTC symbol.

The company states that it has developed a proprietary PIKA® immunomodulating technology platform. Based on available information, this platform underpins a new generation of preventive and therapeutic biologics targeting rabies, hepatitis B, influenza, and other virus infections. These activities place LakeShore Biopharma within the broader biopharmaceutical and vaccine development space, with a focus on infectious disease prevention and treatment as well as immunotherapy-related approaches to cancer.

LakeShore Biopharma, previously known as YS Biopharma, describes itself as operating in China, Singapore, and the Philippines. The company highlights that its management team combines local expertise with global experience in the biopharmaceutical industry. This geographic footprint and management profile suggest an emphasis on research, development, and production activities across several Asian markets, while remaining subject to U.S. securities regulation as a reporting company.

Trading status and market venue

The company has disclosed that its ordinary shares and warrants were previously listed on The Nasdaq Capital Market under the symbol LSB. Following a delisting determination by Nasdaq based on non-compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and ineligibility for an additional compliance period under Listing Rule 5810(c)(3)(A)(iv) due to a prior reverse stock split, trading in its ordinary shares and warrants on Nasdaq was suspended. On the same day, the securities began trading on the OTC Pink Open Market under the symbols LSBCF for the ordinary shares and LSBWF for the warrants.

In its announcements, LakeShore Biopharma emphasized that the transition from Nasdaq to the OTC Market did not change its underlying business operations. The company also stated that it remains a reporting company with the U.S. Securities and Exchange Commission and that it intends to maintain transparency with shareholders and the public through ongoing disclosures.

Corporate evolution and naming

Available information indicates that LakeShore Biopharma was previously known as YS Biopharma. The company now presents itself under the LakeShore Biopharma name while continuing its focus on vaccines and therapeutic biologics. This historical name is relevant for investors reviewing older disclosures or news items that may still reference YS Biopharma.

Business focus and technology platform

LakeShore Biopharma’s stated business focus centers on the development and delivery of vaccines and therapeutic biologics targeting infectious diseases and cancer. The company highlights its proprietary PIKA® immunomodulating technology platform as a core asset. According to its public statements, this platform supports a pipeline of preventive and therapeutic biologics that target rabies, hepatitis B, influenza, and other viral infections. These disclosures indicate an emphasis on immunomodulation and vaccine-related biologics rather than small-molecule drugs.

By concentrating on infectious diseases and cancer, LakeShore Biopharma operates in therapeutic areas where immune response modulation and vaccine efficacy are central concerns. The company’s description of its PIKA® platform suggests that its research and development efforts are organized around this technology and its application to multiple pathogens and disease indications.

Geographic operations and management

The company reports that it operates in China, Singapore, and the Philippines. While specific facility locations or functional roles in each country are not detailed in the provided information, this footprint indicates that LakeShore Biopharma’s activities span multiple jurisdictions in Asia. The company also notes that its management team combines rich local expertise with global experience in the biopharmaceutical industry, which it presents as a strength in navigating both regional and international aspects of vaccine and biologic development.

Going-private transaction

LakeShore Biopharma has announced that it entered into an Agreement and Plan of Merger with Oceanpine Skyline Inc. (Parent) and Oceanpine Merger Sub Inc., a wholly owned subsidiary of Parent. Under this agreement, Merger Sub will merge with and into LakeShore Biopharma, with the company continuing as the surviving entity and becoming a wholly owned subsidiary of Parent in a going‑private transaction. The company has described this as a merger implying a specified equity value and has outlined that, at the effective time of the merger, each ordinary share issued and outstanding immediately prior to that time (other than excluded and dissenting shares, as defined in the merger agreement) will be cancelled in exchange for a cash payment per share.

The company’s board of directors, acting on the unanimous recommendation of a special committee of independent and disinterested directors, approved the merger agreement and the proposed merger and resolved to recommend that shareholders authorize and approve the transaction. Certain shareholders, described as rollover shareholders, have entered into a rollover and support agreement under which they agreed to cancel the shares they hold in exchange for newly issued shares of Parent and to vote their shares in favor of the merger. The company has stated that, if completed, the merger will result in LakeShore Biopharma becoming a privately held company and that its shares will no longer be quoted on the OTC Pink Open Market.

LakeShore Biopharma has indicated that it will furnish a current report on Form 6‑K to the SEC regarding the merger, including the merger agreement as an exhibit, and that it will prepare and mail a proxy statement to shareholders. The company has also stated that a Schedule 13E‑3 transaction statement, including the proxy statement, will be filed with the SEC in connection with the merger.

Status considerations for LSBWF

For the LSBWF symbol, which corresponds to LakeShore Biopharma warrants quoted on the OTC Pink Open Market, the company’s disclosures about its delisting from Nasdaq and its going‑private merger are important context. The transition to the OTC Market followed a Nasdaq delisting determination related to bid price compliance, while the subsequent going‑private agreement, if completed, is expected to result in the company becoming privately held and its shares no longer being quoted on the OTC Pink Open Market. These developments are relevant for investors reviewing the historical and current status of LSBWF and related LakeShore Biopharma securities.

Key points for investors and researchers

• LakeShore Biopharma is a biopharmaceutical company focused on vaccines and therapeutic biologics for infectious diseases and cancer.
• The company has developed the proprietary PIKA® immunomodulating technology platform, which supports biologics targeting rabies, hepatitis B, influenza, and other viral infections.
• It operates in China, Singapore, and the Philippines and describes its management as combining local and global biopharmaceutical experience.
• LakeShore Biopharma, previously known as YS Biopharma, had its ordinary shares and warrants delisted from Nasdaq and transitioned to trading on the OTC Pink Open Market under LSBCF and LSBWF.
• The company remains a reporting company with the SEC and has announced a going‑private merger agreement that, if completed, would result in it becoming a wholly owned subsidiary of Oceanpine Skyline Inc. and its shares no longer being quoted on the OTC Pink Open Market.